Cost-effectiveness of prescription recommendations for cholesterol-lowering drugs: A survey of a representative sample of american cardiologists

Abstract

These findings suggest that the cardiologists' pharmacologic recommendations for lowering lipids are correlated with published cost-effectiveness analyses. However, substantial variation in their recommendations remains, with somewhat less aggressive treatment for secondary prevention and more aggressive treatment for primary prevention than would be recommended on the basis of cost-effectiveness analyses.

Economic Challenge of Cardiovascular Disease

“…Among all the risk factors mentioned above (Chart 1), dyslipidemia is the one that presents the most studies clearly demonstrating the economic and social benefit of measures implemented for its correction [27,28]. The fact that primary prevention has been considered costly should be better elucidated: we know that it is effective (study already published -WOSCOPS) and that it also presents favorable economic results [29,30,31].…”